Used as a potent inhibitor in targeted cancer therapies, particularly in the treatment of non-small cell lung cancer (NSCLC). It functions by selectively inhibiting epidermal growth factor receptor (EGFR) mutations, including T790M and activating mutations, which are implicated in tumor growth and progression. Due to its irreversible binding mechanism, it provides sustained suppression of EGFR signaling, leading to reduced cancer cell proliferation and induction of apoptosis. Its structural design allows improved CNS penetration, making it effective against brain metastases. Commonly employed in oral dosage forms, it is part of precision medicine strategies for patients with specific EGFR mutation profiles.